IMM.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 17:55):

Stats
Šios dienos apimtis	604 698
Vidutinė apimtis	2.75M
Rinkos kapitalizacija	8.91M
EPS	£0 ( 2023-08-31 )
Kita pelno data	( £0 ) 2024-05-08
Last Dividend	£300.00 ( 2021-12-14 )
Next Dividend	£0 ( N/A )
P/E	-2.14
ATR14	£0.0470 (2.20%)

ImmuPharma PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ImmuPharma PLC Finansinės ataskaitos

Annual	2022
Pajamos:	£0
Bruto pelnas:	£-117 563 (0.00 %)
EPS:	£-0.0126

FY	2022
Pajamos:	£0
Bruto pelnas:	£-117 563 (0.00 %)
EPS:	£-0.0126

FY	2021
Pajamos:	£118 350
Bruto pelnas:	£0.00 (0.00 %)
EPS:	£-0.0325

FY	2020
Pajamos:	£126 667
Bruto pelnas:	£0.00 (0.00 %)
EPS:	£-0.0343

Financial Reports:

No articles found.

ImmuPharma PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

ImmuPharma PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	£300.00	2021-12-14
Last Dividend	£300.00	2021-12-14
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	£300.00	--
Avg. Dividend % Per Year	240.00%	--
Score	4.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-28)

£0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

4.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2021	£300.00	2 400.00%
2022	£0	0.00%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
VIC.L	Dividend Knight	2023-06-08	Semi-Annually	2	0.88%
MRO.L	Dividend Junior	2023-09-14	Semi-Annually	19	2.42%
DNA3.L	Dividend Royal	2023-07-20	Quarterly	12	10.69%
SHOE.L	Dividend Knight	2023-07-13	Annually	10	2.57%
III.L	Dividend King	2023-06-22	Semi-Annually	31	1.93%
BOWL.L	Dividend Knight	2023-06-08	Annually	8	1.03%
OOA.L	Dividend Knight	2023-07-27	Semi-Annually	17	2.87%
ETP.L	Dividend Knight	2023-08-17	Annually	3	0.19%
STEM.L	Dividend Knight	2023-11-09	Annually	19	1.82%
JTC.L	Dividend Knight	2023-09-21	Semi-Annually	7	0.79%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-32.54	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-1.038	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-1.708	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.169	0.800	9.15	7.32	[1 - 3]
quickRatioTTM	0.970	0.800	9.00	7.20	[0.8 - 2.5]
cashRatioTTM	0.136	1.500	-0.357	-0.535	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-2.58	1.000	-2.07	-2.07	[3 - 30]
operatingCashFlowPerShareTTM	-0.00502	2.00	-0.00167	-0.00334	[0 - 30]
freeCashFlowPerShareTTM	-0.00533	2.00	-0.00267	-0.00533	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	-0.326	1.000	-8.76	-8.76	[0.2 - 0.8]
operatingProfitMarginTTM	-31.51	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.0319	0.800	-3.12	-2.50	[0.5 - 2]
Total Score				-4.45

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.09	1.000	-0.312	0	[1 - 100]
returnOnEquityTTM	-1.708	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.00533	2.00	-0.00178	-0.00533	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.00502	2.00	-0.00167	-0.00334	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.846	1.500	-8.97	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-15.93	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-3.03

ImmuPharma PLC

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.